目的:观察电针对颅脑外伤昏迷患者大脑中线及环池的影响。方法:选取重度颅脑损伤昏迷患者60例,按照随机数字表法分为对照组及电针组,每组30例。对照组给予常规治疗,电针组在对照组治疗的基础上加用电针治疗。观察两组患者治疗前后格拉...目的:观察电针对颅脑外伤昏迷患者大脑中线及环池的影响。方法:选取重度颅脑损伤昏迷患者60例,按照随机数字表法分为对照组及电针组,每组30例。对照组给予常规治疗,电针组在对照组治疗的基础上加用电针治疗。观察两组患者治疗前后格拉斯哥昏迷评分(glasgow coma scale,GCS)变化情况,对比两组治疗后1个月格拉斯哥预后分级(glasgow outcome score,GOS)、CT下大脑中线移位及环池形态变化情况。结果:两组患者治疗后、治疗后1个月GCS评分均高于治疗前(P<0.05),且电针组高于对照组,差异有统计学意义(P<0.05)。电针组治疗后1个月GCS评分、GOS分级优于对照组,差异有统计学意义(P<0.05)。运用CT行颅脑扫描示,中线移位>10mm者,电针组少于对照组,环池宽度>3mm者,电针组多于对照组,差异有统计学意义(P<0.05)。结论:电针治疗可提高颅脑外伤昏迷患者GCS评分,改善GOS分级,减轻患者继发性脑损伤,其机制可能与促进患者大脑中线移位及环池形态恢复相关。展开更多
Insomnia and related sleep disorders (somnipathies) affect a large segment of the population, and result in a significant negative impact on quality of life and reduced or lost productivity. The speed of sleep onset i...Insomnia and related sleep disorders (somnipathies) affect a large segment of the population, and result in a significant negative impact on quality of life and reduced or lost productivity. The speed of sleep onset is a critical characteristic of successful pharmacotherapeutic intervention for insomnia. Zolpidem, a non-benzodiazepine benzodiazepine receptor agonist (nBzRA) is widely used to treat insomnia. Although not itself a benzodiazepine (BZD), zolpidem has high binding affinity for the benzodiazepine receptor, which acts as a positive allosteric modulator of the GABAA receptor complex. It therefore increases the neuronal transmembrane influx of Cl- ions, thereby decreasing neuronal excitability and promoting sleep. In this four-way crossover, dose-ranging, multiple-treatment study, a lingual spray formulation of zolpidem was safe and well-tolerated and yielded more rapid pharmacokinetics (mean plasma concentration) and efficacy (visual analog scale and digit symbol substitution test) compared to oral tablets.展开更多
文摘目的:观察电针对颅脑外伤昏迷患者大脑中线及环池的影响。方法:选取重度颅脑损伤昏迷患者60例,按照随机数字表法分为对照组及电针组,每组30例。对照组给予常规治疗,电针组在对照组治疗的基础上加用电针治疗。观察两组患者治疗前后格拉斯哥昏迷评分(glasgow coma scale,GCS)变化情况,对比两组治疗后1个月格拉斯哥预后分级(glasgow outcome score,GOS)、CT下大脑中线移位及环池形态变化情况。结果:两组患者治疗后、治疗后1个月GCS评分均高于治疗前(P<0.05),且电针组高于对照组,差异有统计学意义(P<0.05)。电针组治疗后1个月GCS评分、GOS分级优于对照组,差异有统计学意义(P<0.05)。运用CT行颅脑扫描示,中线移位>10mm者,电针组少于对照组,环池宽度>3mm者,电针组多于对照组,差异有统计学意义(P<0.05)。结论:电针治疗可提高颅脑外伤昏迷患者GCS评分,改善GOS分级,减轻患者继发性脑损伤,其机制可能与促进患者大脑中线移位及环池形态恢复相关。
文摘Insomnia and related sleep disorders (somnipathies) affect a large segment of the population, and result in a significant negative impact on quality of life and reduced or lost productivity. The speed of sleep onset is a critical characteristic of successful pharmacotherapeutic intervention for insomnia. Zolpidem, a non-benzodiazepine benzodiazepine receptor agonist (nBzRA) is widely used to treat insomnia. Although not itself a benzodiazepine (BZD), zolpidem has high binding affinity for the benzodiazepine receptor, which acts as a positive allosteric modulator of the GABAA receptor complex. It therefore increases the neuronal transmembrane influx of Cl- ions, thereby decreasing neuronal excitability and promoting sleep. In this four-way crossover, dose-ranging, multiple-treatment study, a lingual spray formulation of zolpidem was safe and well-tolerated and yielded more rapid pharmacokinetics (mean plasma concentration) and efficacy (visual analog scale and digit symbol substitution test) compared to oral tablets.
